查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967834

2026-2034年人工智慧（AI）驅動藥物發現全球市場規模、佔有率、趨勢和成長分析報告

Global Artificial Intelligence (AI) in Drug Discovery Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計人工智慧（AI）在製藥開發領域的市場規模將從2025年的33.6億美元成長到2034年的356.8億美元，2026年至2034年的複合年成長率為30.04%。

隨著製藥公司尋求縮短研發時間和降低研發成本，人工智慧在藥物發現領域的市場正經歷顯著成長。機器學習、深度學習和自然語言處理等人工智慧技術正被用於識別藥物標靶、預測分子行為以及最佳化臨床候選化合物的選擇。生技Start-Ups與大型製藥企業之間合作的加強，正在加速人工智慧在早期研發階段的應用。

關鍵促進因素包括藥物研發成本不斷上漲、提高成功率的需求以及取得大量生物醫學數據。人工智慧平台能夠增強標靶檢驗、化合物篩檢和毒性預測，從而縮短藥物發現週期。運算能力的進步和基於雲端的分析技術進一步提升了擴充性。創業投資對人工智慧主導生物技術公司的投入正在推動創新並拓展競爭格局。

未來，人工智慧有望成為藥物研發全過程不可或缺的一部分，包括臨床試驗設計和真實世界數據分析。與基因組學、蛋白質組學和患者數據的整合將實現更精準的治療方法。監管機構對人工智慧產生的洞見和數據透明度的認可預計將對長期發展產生影響。隨著演算法的成熟和檢驗準確性的提高，人工智慧主導的開發平臺有望顯著變革藥物創新。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球人工智慧（AI）藥物研發市場：按應用領域分類

  • 市場分析、洞察與預測
  • 藥物最佳化和再利用
  • 臨床前試驗
  • 其他

第5章：全球藥物研發市場－人工智慧（AI）應用：依治療領域分類

  • 市場分析、洞察與預測
  • 腫瘤學
  • 神經退化性疾病
  • 心血管疾病
  • 代謝性疾病
  • 感染疾病
  • 其他

第6章：全球人工智慧（AI）藥物發現市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • IBM Corporation
    • Exscientia Plc
    • Insilico Medicine Inc
    • Aitia（Formerly GNS Healthcare）
    • Google DeepMind
    • BenevolentAI
    • BioSymetrics Inc
    • Berg Health（Acquired By BPGbio）
    • Atomwise Inc
    • Insitro
    • Cyclica（Now Part Of Recursion Pharmaceuticals）
簡介目錄
Product Code: VMR11218721

The Artificial Intelligence (AI) in Drug Discovery Market size is expected to reach USD 35.68 Billion in 2034 from USD 3.36 Billion (2025) growing at a CAGR of 30.04% during 2026-2034.

The AI in drug discovery market has witnessed significant growth as pharmaceutical companies seek to reduce R&D timelines and costs. AI technologies-such as machine learning, deep learning, and natural language processing-are used to identify drug targets, predict molecular behavior, and optimize clinical candidate selection. Growing collaboration between biotech startups and large pharmaceutical firms has accelerated AI adoption in early-stage research.

Primary drivers include rising drug development costs, the need for higher success rates, and access to vast biomedical datasets. AI platforms enhance target validation, compound screening, and toxicity prediction, shortening discovery cycles. Advances in computational power and cloud-based analytics further support scalability. Venture capital investment in AI-driven biotech firms has fueled innovation and expanded the competitive landscape.

Looking ahead, AI is expected to become integral across the drug development continuum, including clinical trial design and real-world evidence analysis. Integration with genomics, proteomics, and patient data will enable more precise therapies. Regulatory acceptance of AI-generated insights and data transparency will influence long-term growth. As algorithms mature and validation improves, AI-driven pipelines may significantly reshape pharmaceutical innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

  • Drug Optimization and Repurposing
  • Preclinical Testing
  • Others

By Therapeutic Area

  • Oncology
  • Neurodegenerative Diseases
  • Cardiovascular Disease
  • Metabolic Diseases
  • Infectious Disease
  • Others

COMPANIES PROFILED

  • IBM Corporation, Exscientia plc, Insilico Medicine Inc, Aitia formerly GNS Healthcare, Google DeepMind, BenevolentAI, BioSymetrics Inc, Berg Health acquired by BPGbio, Atomwise Inc, insitro, Cyclica now part of Recursion Pharmaceuticals
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Drug Optimization and Repurposing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Neurodegenerative Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Cardiovascular Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Application
    • 6.2.2 By Therapeutic Area
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Application
    • 6.3.2 By Therapeutic Area
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Application
    • 6.4.2 By Therapeutic Area
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Application
    • 6.5.2 By Therapeutic Area
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Application
    • 6.6.2 By Therapeutic Area
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 IBM Corporation
    • 8.2.2 Exscientia Plc
    • 8.2.3 Insilico Medicine Inc
    • 8.2.4 Aitia (Formerly GNS Healthcare)
    • 8.2.5 Google DeepMind
    • 8.2.6 BenevolentAI
    • 8.2.7 BioSymetrics Inc
    • 8.2.8 Berg Health (Acquired By BPGbio)
    • 8.2.9 Atomwise Inc
    • 8.2.10 Insitro
    • 8.2.11 Cyclica (Now Part Of Recursion Pharmaceuticals)